About

Pancreatic ductal adenocarcinoma is the most common form of pancreatic cancer and one of the deadliest solid tumors, with fewer than one in ten people alive five years after diagnosis. Rasonque is an oral medicine that binds RAS proteins while they are switched on, blocking the growth signals that keep tumor cells dividing. Because most pancreatic tumors are driven by RAS mutations, shutting down that signal could potentially slow tumor growth in people whose cancer has already been treated.